商品名称 | 适用类别 | 通用名称 | 活性成分 | 产品号 | 上市许可开发者/申请人/持有人 | 上市许可日期 | 许可状态 |
---|---|---|---|---|---|---|---|
Wyost | Human | denosumab | denosumab | EMEA/H/C/006378 | Sandoz GmbH | 2024/05/17 | Authorised |
Jubbonti | Human | denosumab | denosumab | EMEA/H/C/005964 | Sandoz GmbH | 2024/05/16 | Authorised |
Xgeva | Human | denosumab | denosumab | EMEA/H/C/002173 | Amgen Europe B.V. | 2011/07/13 | Authorised |
Prolia | Human | denosumab | denosumab | EMEA/H/C/001120 | Amgen Europe B.V. | 2010/05/26 | Authorised |
Stoboclo | Human | denosumab | denosumab | EMEA/H/C/006156 | Celltrion Healthcare Hungary Kft. | Opinion | |
Osenvelt | Human | denosumab | denosumab | EMEA/H/C/006157 | Celltrion Healthcare Hungary Kft. | Opinion | |
Obodence | Human | denosumab | denosumab | EMEA/H/C/006424 | Samsung Bioepis NL B.V. | Opinion | |
Xbryk | Human | denosumab | denosumab | EMEA/H/C/006468 | Samsung Bioepis NL B.V. | Opinion |